J&J's Tecvayli-Talvey combo cuts myeloma progression risk 89% in Phase 3
MonumenTAL-6 topline data show the GPRC5D-BCMA bispecific pairing beat standard-of-care regimens on progression-free survival, with an independent monitoring committee unblinding the trial early on the strength of the effect.
Executive Summary
- A Phase 3 trial combining two of Johnson & Johnson's approved multiple myeloma bispecific antibodies met its primary endpoint, cutting the risk of disease progression or death against standard-of-care regimens by a wide margin.
- The trial pairs two distinct T-cell engaging mechanisms, one targeting BCMA and one targeting GPRC5D, against the two combination regimens more commonly used in this relapsed and refractory setting, moving an already-approved late-line therapy earlier in treatment.
- The disclosed results are topline hazard ratios from an interim analysis, unblinded early on the strength of the effect, without mature survival medians or full safety detail yet reported.
- The result lands in a bispecific antibody field that already includes several approved and late-stage GPRC5D- and BCMA-targeted competitors, reinforcing J&J's position rather than opening new mechanistic ground.
The result
Johnson & Johnson announced topline data from MonumenTAL-6 (NCT06208150), a three-arm Phase 3 trial testing Tecvayli plus Talvey (Tec-Tal) and Talvey plus pomalidomide (Tal-P) against investigator's choice of elotuzumab-pomalidomide-dexamethasone or pomalidomide-bortezomib-dexamethasone in patients who had received an anti-CD38 antibody and lenalidomide. Both investigational arms met the trial's primary endpoint of progression-free survival with statistically significant improvements over standard of care. The Tec-Tal arm reduced the risk of progression or death by 89% (hazard ratio 0.11, 95% CI 0.08-0.16, p<0.0001) and the risk of death by 62% (hazard ratio 0.38); the Tal-P arm reduced progression or death risk by 73% (hazard ratio 0.27, 95% CI 0.2-0.35). NCT06208150+1A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideNCT06208150TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myelomaJul 23, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
How it was run
The trial enrolled 795 patients with relapsed or refractory multiple myeloma who had received one to four prior lines of therapy, including an anti-CD38 antibody and lenalidomide, and an ECOG performance status of 0 to 2. It is an open-label, randomized, three-arm design run across the United States, China, Japan, Spain and Brazil, structured as a registrational study. The Independent Data Monitoring Committee recommended unblinding the trial at its first interim analysis based on the strength of the observed effect, and the overall safety profiles of both combination arms were described as consistent with the known safety profiles of each drug as monotherapy. Emory University's Ajay Nooka said the findings add "to a growing body of Phase 3 evidence evaluating the survival outcomes associated with the early use of immunotherapy doublets in the treatment journey". NCT06208150+1A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideNCT06208150TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myelomaJul 23, 2026
What the disclosure omits
The reported figures are relative hazard ratios drawn from an interim analysis; no median progression-free survival, overall survival, or response-rate figures accompanied the release, and full data are still to be presented at a future medical meeting and shared with health authorities. Both Tecvayli and Talvey already carry accelerated approvals as monotherapies for more heavily pretreated multiple myeloma, so the trial's registrational purpose here is to move the combination into an earlier treatment line rather than establish a first mechanism of action. TECVAYLI+1TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myelomaJul 23, 2026A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideNCT06208150
Competitive field
The GPRC5D-targeted bispecific field includes Pfizer's elranatamab, Regeneron's linvoseltamab, and GlaxoSmithKline's belantamab mafodotin, alongside cell-therapy comparators such as Janssen's own ciltacabtagene autoleucel and Celgene's idecabtagene vicleucel, all active in Phase 3 or Phase 4 multiple myeloma trials. J&J is running an additional Phase 3 GPRC5D bispecific asset, ramantamig, in the same indication. Historical data in this class show a 50% termination rate across resolved GPRC5D-times-multiple myeloma trials, with two sponsors having discontinued programs in the space, underscoring that the mechanism has not been uniformly successful even as J&J's own combination clears its primary endpoint.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.